NASDAQ · LXRX
Healthcare · Biotechnology
$2.32
Down-$0.03 (-1.30%)
Updated Aug 28, 2026, 3:19 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
LXRX closed at $2.32 after 21 trading sessions, down 0.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $2.30 | $2.339 | $2.295 | $2.32 | 1.62M |
| Aug 26, 2026 | $2.32 | $2.3488 | $2.28 | $2.31 | 1.2M |
| Aug 25, 2026 | $2.35 | $2.365 | $2.30 | $2.34 | 1.82M |
| Aug 24, 2026 | $2.32 | $2.35 | $2.295 | $2.32 | 1.68M |
| Aug 21, 2026 | $2.19 | $2.31 | $2.19 | $2.30 | 3.19M |
| Aug 20, 2026 | $2.40 | $2.40 | $2.17 | $2.18 | 4.75M |
| Aug 19, 2026 | $2.46 | $2.475 | $2.39 | $2.41 | 1.78M |
| Aug 18, 2026 | $2.33 | $2.44 | $2.325 | $2.42 | 2.9M |
| Aug 17, 2026 | $2.31 | $2.39 | $2.2895 | $2.34 | 3.53M |
| Aug 14, 2026 | $2.32 | $2.335 | $2.265 | $2.32 | 1.76M |
| Aug 13, 2026 | $2.37 | $2.39 | $2.32 | $2.34 | 2.32M |
| Aug 12, 2026 | $2.41 | $2.455 | $2.35 | $2.35 | 2.57M |
| Aug 11, 2026 | $2.42 | $2.45 | $2.31 | $2.43 | 3.03M |
| Aug 10, 2026 | $2.45 | $2.49 | $2.38 | $2.40 | 2.7M |
| Aug 7, 2026 | $2.435 | $2.475 | $2.29 | $2.47 | 3.09M |
| Aug 6, 2026 | $1.96 | $2.44 | $1.96 | $2.36 | 4.89M |
| Aug 5, 2026 | $2.515 | $2.515 | $2.40 | $2.45 | 3.97M |
| Aug 4, 2026 | $2.33 | $2.52 | $2.32 | $2.49 | 3.91M |
| Aug 3, 2026 | $2.29 | $2.34 | $2.22 | $2.33 | 2.05M |
| Jul 31, 2026 | $2.32 | $2.35 | $2.245 | $2.31 | 2.77M |
| Jul 30, 2026 | $2.32 | $2.40 | $2.285 | $2.34 | 2.46M |
The latest Smart Investors Daily articles mentioning LXRX.
LXRX research
Company profile and research snapshot.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 11, 2026 | Citigroup | Buy | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 10, 2026 | Citigroup | Buy | — |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 2, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 19, 2026
Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last...
SeekingAlpha · Aug 10, 2026
2026-08-10. The following slide deck was published by Lexicon Pharmaceuticals, Inc.
ChartMill · Aug 6, 2026
Lexicon Pharma Q2 revenue misses at $0.7M vs $4.08M expected; EPS loss wider. Shares dip 1.6% as pipeline milestones advance.
SeekingAlpha · Aug 6, 2026
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call August 6, 2026 8:30 AM EDTCompany ParticipantsLisa DeFrancesco - Senior Vice President of...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LXRX.
